Ewingov sarkóm – naše skúsenosti s liečbou // SOLEN

Onkológia 1/2019

Ewing sarcoma – our treatment experiences

Purpose: Ewing sarcoma is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents. Data that document the effectiveness of the current approach in the adult patient population are limited. The study outcome was to evaluate overall survival, objective response rate and progression-free survival. Patients and methods: We performed a retrospective review including all Ewing sarcoma patients older than 18 years of age (with median 42 years) who received systemic therapy between 2012 and 2017 at institution. Results: 16 patients with Ewing sarcoma were identified. The median overall survival for the entire group was 24 months and the time to progression was 18 months. In patients with metastatic disease the median OS was 22 months and PFS 18 months. Conclusion: Our data show similar efficacy in comparison with younger patients.

Keywords: Ewing sarcoma, adult, bone cancer, chemotherapy, overall survival, progression-free survival